Evidence map›Paper›PMID 35214610›Full record

ArticleVaccines2022

Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies.

Osman O Radhwi, Hamza Jan, Abdullah Waheeb, Sawsan S Alamri, Hatem M Alahwal, Iuliana Denetiu, Ashgan Almanzlawey, Adel F Al-Marzouki, Abdullah T Almohammadi, Salem M Bahashwan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Osman O RadhwiHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.ORCID 0000-0002-1578-3998
Hamza JanHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Abdullah WaheebHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Sawsan S AlamriVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Hatem M AlahwalHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Iuliana DenetiuHematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.ORCID 0000-0002-7803-2761
Ashgan AlmanzlaweyHematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Adel F Al-MarzoukiHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Abdullah T AlmohammadiHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Salem M BahashwanHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Ahmed S BarefahHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.ORCID 0000-0003-2009-3817
Mohamad H QariHematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Adel M AbuzenadahDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Anwar M HashemVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.ORCID 0000-0002-8471-7011
King Abdulaziz University · SA

Funding

Deanship of Scientific Research, King Abdulaziz University GCV19-43-1441
6 · The paper itself

Abstract

introductionStudies assessing immune responses following Pfizer-BioNTech BNT162b2 mRNA COVID-19 (Pfizer) and ChAdOx1 nCoV-19 AZD1222 (AstraZeneca) vaccines in patients with hemoglobinopathy are non-existent in the literature despite being thought at high risk of infection.

methodsProspectively, we collected serum from patients with hemoglobinopathies at least 14 days post vaccine and measured neutralizing antibodies (nAb) in addition to binding antibodies using in-house assays.

resultsAll 66 participants mounted a significant binding antibody response (100%), but nAbs were detected in (56/66) post-vaccine with a rate of 84.5%. Age, gender, vaccine type, spleen status, hydroxyurea use, and hyperferritinemia did not affect the rate significantly. While 23/32 (71.8%) patients receiving only one dose of the vaccine were able to mount a positive response, 33/34 (97.05%) of those who had two doses of any vaccine type had a significant nAbs response. Patients who had anti-nucleocapsid (N), signifying asymptomatic infection in the past, were able to produce nAbs (31/31). No nAbs were detected in 10/35 (28.5%) patients with no anti-N antibodies.

conclusionOur results provide supportive data when advising patients with hemoglobinopathy to receive COVID-19 vaccines and ensure booster doses are available for better immunity. Whenever available, measurement of nAb is recommended.

Indexed as

BNT162b2ChAdOx1 nCoV-19COVID-19sickle cell diseasethalassemiavaccine

Identifiers

PMID35214610
PMCPMC8877446
OpenAlexW4206531078

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.